Skip to NavigationSkip to content

Fast-acting mealtime insulin approved for children with diabetes in Canada

Published on 10/03/20 at 09:34am
Photo by Alan Levine

Health Canada has approved Novo Nordik’s Fiasp, a faster acting mealtime insulin, for children aged 2 and above with type 1 or type 2 diabetes.

The regulatory body also approved Fiasp to include use in insulin infusion pumps for the improvement of glycemic control.

Dave Prowten, President and CEO of JDRF Canada, said on the approval: “We welcome the paediatric approval of Fiasp for younger Canadians, providing greater choice for effective disease management to support easier, healthier and safer lives for young people with type 1 diabetes.”

Health Canada’s approval is based on a review of the onset 7 clinical trial which confirmed the efficacy and safety of Fiasp in children. Fiasp vials may now be used for continuous subcutaneous insulin infusion in pump systems that are licensed in Canada for insulin infusion.

Vicky Chan, Vice President, Clinical Development, Medical and Regulatory Affairs, at Novo Nordisk Canada Inc, said: “We are pleased to offer Fiasp – a trusted and effective mealtime glucose control treatment – to the paediatric diabetes community in Canada allowing for choice and convenience in supporting diabetes management goals.” 

Fiasp was created with the goal to achieve a faster initial absorption rate, to improve glycaemic control after a meal, in people with diabetes.

Conor Kavanagh

 

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches